

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Substitute for Form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete If Known	
				Application Number	09/913,911
				Filing Date	August 21, 2001
				First Named Inventor	Daniela Santoli et al
				Group Art Unit	1633-1644
				Examiner Name	M. D.
Sheet	2	of	6	Attorney Docket Number	WST88AUSA

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
AD	AF	5,747,024	B1	K. Grabstein	05/05/1998	
AD	AG	5,660,824	B1	K. Grabstein	08/26/1997	
AD	AH	6,022,538	B1	D. Santoli	02/08/2000	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)				

Examiner Signature		Date Considered	2/2/04
--------------------	--	-----------------	--------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Substitute for Form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			Complete If Known		
			Application Number	09/913,911	
			Filing Date	August 21, 2001	
			First Named Inventor	Daniela Santoli et al	
			Group Art Unit	4633-1644	
			Examiner Name	M. D.	
Sheet	3	of	6	Attorney Docket Number	WST88AUSA

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiners Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T‡	
MD	AR	A. GAMERO et al, "Interleukin 15 Induction of Lymphokine-activated Killer Cell Function Against Autologous Tumor Cells in Melanoma Patient Lymphocytes by a CD18-Dependent, Perforin-related Mechanism", Cancer Research, 55:4988-4994 (November, 1995)		
MD	AS	A. CESANO et al, "Two Unique Human Leukemic T-Cell Lines Endowed with a Stable Cytotoxic Function and a Different Spectrum of Target Reactivity Analysis and Modulation of Their Lytic Mechanisms", In Vitro Cell. Dev. Biol., 28A:648-656 (September-October, 1992)		
MD	AT	A. CESANO et al, "Effects of Lethal Irradiation and Cyclosporin A Treatment on the Growth and Tumoricidal Activity of a T Cell Clone Potentially Useful in Cancer Therapy", Cancer Immunol. Immunother., 40:139-151 (1995)		
MD	AU	D. SANTOLI et al, "Synergistic and Antagonistic Effects of IL-1α and IL-4, Respectively, on the IL-2-Dependent Growth of a T Cell Receptor-γδ+ Human T Leukemia Cell Line", J. Immunol., 144(12):4703-4711 (June, 1990)		
MD	AV	J. DISANTO, "Cytokines: Shared Receptors, Distinct Functions", Current Biology, 7:R424-R426 (July, 1997)		
MD	AW	B. ROUSE et al, "Consequences of Exposure to Ionizing Radiation for Effector T Cell Function in Vivo", Viral Immunology, 2(2):69-78 (1989)		
MD	AX	T. HAN et al, "Stimulating Capacity of Blast Cells from Patients with Chronic Myelocytic Leukaemia, in Blastic Crisis in 'one-way' Mixed Lymphocyte Reaction: Lack of Evidence for T Lymphoblastic Conversion", Immunology, 35:299-305 (1978)		

Examiner Signature		Date Considered	2/2/04
--------------------	--	-----------------	--------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Unique citation designation number. ‡Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Substitute for Form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			Complete if Known		
			Application Number	09/913,911	
			Filing Date	August 21, 2001	
			First Named Inventor	Daniela Santoli et al	
			Group Art Unit	1633 1644	
			Examiner Name	M. D. B.	
Sheet	4	of	6	Attorney Docket Number	WST88AUSA

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiners Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
ND	AY	K. FOON, "Biological Response Modifiers: The New Immunotherapy", Cancer Research, 49:1621-1639 (April, 1989)	
ND	AZ	T. BOON, "Tumor Antigens Recognized by Cytolytic T Lymphocytes: Present Perspectives for Specific Immunotherapy", Int. J. Cancer, 54:177-180 (1993)	
ND	AAR	M. OSBAND et al, "Problems in the Investigational Study and Clinical Use of Cancer Immunotherapy", Immunology Today, 11(6):103-105 (1990)	
ND	AAS	A. CESANO et al, "Phase I Clinical Trial with a Human Major Histocompatibility Complex Nonrestricted Cytotoxic T-Cell Line (TALL-104) in Dogs with Advanced Tumors", Cancer Research, 56:3021-3029 (July, 1996)	
ND	AAT	R. O'CONNOR et al, "Growth Factor-Dependent Differentiation Along the Myeloid and Lymphoid Lineages in an Immature Acute T Lymphocytic Leukemia", J. Immunol., 145(11):3779-3787 (December, 1990)	
ND	AAU	S. CHAN et al, "Mechanisms of IFN- $\gamma$ Induction by Natural Killer Cell Stimulatory Factor (NKSF/IL-12)", J. Immunol., 148(1):92-98 (January 1992)	
ND	AAV	R. O'CONNOR et al, "Growth Factor Requirements of Childhood Acute T-Lymphoblastic Leukemia: Correlation Between Presence of Chromosomal Abnormalities and Ability to Grow Permanently In Vitro", Blood, 77(7):1534-1545 (April, 1991)	
ND	AAW	A. CESANO et al, "Cellular and Molecular Mechanisms of Activation of MHC Nonrestricted Cytotoxic Cells by IL-12", 151:2943-2957 (1993)	

Examiner Signature		Date Considered	2/2/04
--------------------	--	-----------------	--------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Substitute for Form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete If Known		
				Application Number	09/913,911	
				Filing Date	August 21, 2001	
				First Named Inventor	Daniela Santoli et al	
				Group Art Unit	1633-1644	
				Examiner Name	M. R.	
Sheet	5	of	6	Attorney Docket Number		WST88AUSA

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiners Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
WP	AAX	S. VISONNEAU et al, "A Revertant TCR $\gamma\delta$ + Cell Clone Which has Lost MHC Nonrestricted Cytotoxic Activity but Retains Redirected Killing Upon Stimulation of the CD3 Receptor", Cell. Immunol., 165:252-265 (1995)	
WP	AAY	A. CESANO et al, "Role of CD38 and its Ligand in the Regulation of MHC Nonrestricted Cytotoxic T Cells", J. Immunol., 160:1106-1115 (1998)	
WP	AAZ	J. GIRI et al, "IL-5, a Novel T Cell Growth Factor that Shares Activities and Receptor Components with IL-2", J. Leuko. Biol., 57(5):763-766 (May, 1995)	
WP	BR	L. QUINN et al, Interleukin-15: A Novel Anabolic Cytokine for Skeletal Muscle", Endocrinol., 136(8):3669-3672 (August, 1995)	
WP	BS	W. CARSON et al, "Endogenous Production of Interleukin 15 by Activated Human Monocytes is Critical for Optimal Production of Interferon-gamma by Natural Killer Cells in Vitro", J. Clin. Invest., 96(6):2578-2582 (December, 1995)	
WP	BT	J. JONULEIT et al, "Induction of IL-15 Messenger RNA and Protein in Human Blood-Derived Dendritic Cells", J. Immunol., 158(6):2610-2615 (March, 1997)	
WP	BU	V. GARCIA et al, "IL-15 Enhances the Response of Human $\gamma\delta$ T Cells to Nonpeptide Microbial Antigens", J. Immunol., 160(9):4322-4329 (May, 1998)	
WP	BV	A. MORI et al, "IL-15 Promotes Cytokine Production of Human T Helper Cells", J. Immunol., 156(7):2400-2405 (April, 1996)	
WP	BW	M. NIETO et al, Interleukin-15 Induces Adhesion Receptor Redistribution in T Lymphocytes", Euro. J. Immunol., 26(6):1302-1307 (June, 1996)	

Examiner Signature		Date Considered	2/2/04
-----------------------	--	--------------------	--------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Substitute for Form 1449/PTO <b>INFORMATION DISCLOSURE          STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete If Known	
				Application Number	09/913,911
				Filing Date	August 21, 2001
				First Named Inventor	Daniela Santoli et al
				Group Art Unit	4633 <i>1644</i>
				Examiner Name	<i>m m</i>
Sheet	6	of	6	Attorney Docket Number	WST88AUSA

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiners Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
<i>MP</i>	BX	M. KENNEDY et al, "Characterization of Interleukin-15 (IL-15) and the IL-15 Receptor Complex", J. Clin. Immunol., 16(3):134-143 (May, 1996)		
<i>MP</i>	BY	A. ANGIOLILLO et al, "Interleukin-15 Promotes Angiogenesis in Vivo", Biochem. Biophys. Res. Comm., 233(1):231-237 (April, 1997)		
<i>MP</i>	BZ	P. ALLAVENA et al, "IL-15 is Chemotactic for Natural Killer Cells and Stimulates their Adhesion to Vascular Endothelium", J. Leuko. Biol., 61(6):729-735 (June, 1997)		
<i>MP</i>	BBR	R. EVANS et al, IL-15 Mediates Anti-tumor Effects after Cyclophosphamide Depletion of Tumor-Bearing Mice and Enhances Adoptive Immunotherapy: The Potential Role of NK Cell Subpopulations", Cell. Immunol., 179(1):66-73 (July, 1997)		

Examiner Signature	<i>m m</i>	Date Considered	2/2/04
--------------------	------------	-----------------	--------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Substitute for Form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application Number	09/913,911
				Filing Date	August 21, 2001
				First Named Inventor	Daniela Santoli et al
				Group Art Unit	1633-1644
Examiner Name	M. D.				
Sheet	1	of	6	Attorney Docket Number	WST88AUSA

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
MD	AA	5,126,132	B1	S. Rosenberg	06/30/1992	
MD	AB	5,272,082	B1	D. Santoli	12/21/1993	
MD	AC	5,820,856	B1	D. Santoli	10/13/1998	
MD	AD	5,702,702	B1	D. Santoli	12/30/1997	
MD	AE	5,683,690	B1	D. Santoli	11/04/1997	

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)				
MB	AL	WO	WO94/26284	A1	D. Santoli	11/24/1994		
MB	AM	WO	WO98/48630	A1	D. Santoli	11/05/1998		

Examiner Signature		Date Considered	2/2/04
--------------------	--	-----------------	--------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

# RECEIVED

MAR 15 2002

TECH CENTER 1600/2900

PTO/SB/08B (08-00)

Please type a plus sign (+) inside this box → ☐

Substitute for Form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	09/913,911
				Filing Date	August 21, 2001
				First Named Inventor	Daniela Santoli et al
				Group Art Unit	1633-1644
				Examiner Name	M. D. [Signature]
Sheet	2	of	2	Attorney Docket Number	WST88AUSA



OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiners Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>	
WJ	BBS	W. CARSON et al, "Interleukin (IL) 15 is a Novel Cytokine that Activates Human Natural Killer Cells via Components of the IL-2 Receptor", J. Exp. Med., 180(4):1395-1403 (1994)		
WJ	BBT	H. KANEGANE et al, "Activation of Naive and Memory T Cells by Interleukin-15", Blood, 88(1):230-235 (July, 1996)		

Examiner Signature	[Signature]	Date Considered	2/2/02
--------------------	-------------	-----------------	--------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

# RECEIVED

MAR 15 2002

Please type a plus sign (+) inside this box → ☐

TECH CENTER 1600/2900

PTO/SB/08A (08-00)

Substitute for Form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application Number	09/913,911
				Filing Date	August 21, 2001
				First Named Inventor	Daniela Santoli et al
				Group Art Unit	1633-1644
				Examiner Name	M. DiBenedetto
Sheet	1	of	2	Attorney Docket Number	WST88AUSA

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)				
MD	AN	WO	WO95/27722	A1	K. Grabstein	10/19/1995		

Examiner Signature		Date Considered	2/2/02
--------------------	--	-----------------	--------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.